Biomarker panel for colorectal cancer

• US 20080206756A1
• Filed: 07/12/2007
• Published: 08/28/2008
• Est. Priority Date: 07/18/2003
• Status: Abandoned Application

• Current Assignee: Sutter Bay Hospitals
• Original Assignee: California Pacific Medical Center (Sutter Health)
• Inventors: Lee, Nancy M., Chen, Ling-Chun
• Application Number:
  US11/827,894
• Publication Number:
  US 20080206756A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

A panel of biomarkers has been identified for analysis of colorectal cancer. The panel, originally identified using a mouse colon cancer model, has been used to assess changes in human tissue from surgical and biopsy samples against a normal human control panel of biomarkers. The panel may be used for providing a cost effective, rapid, noninvasive procedure for risk assessment, early diagnosis, establishing prognosis, monitoring patient treatment, detecting relapse, and for the discovery of therapeutic intervention of colorectal cancer.

Claims

1-95. -95. (canceled)

96. A method of detecting colorectal cancer in a subject, comprising:

(i) swabbing the rectum to collect colorectal cells from the subject;

(ii) measuring the expression level of IL-8 in the collected cells; and

(iii) comparing the level of IL-8 expression in the collected cells to the level of IL-8 expression in cells from normal rectal cells;

where an increase in expression of IL-8, relative to cells from normal rectal cells, is indicative of colorectal cancer.

97. The method of claim 96, wherein the expression level comprises measuring mRNA.

98. The method of claim 96, wherein the expression level comprises measuring cDNA.

99. The method of claim 96, wherein the measuring is via reverse transcriptase PCR.

100. The method of claim 96, wherein IL-8 comprises SEQ ID NO:

1 or variants thereof.

101. The method of claim 96, wherein the measuring of IL-8 comprises PCR amplification with an oligonucleotide primer pair comprising SEQ ID NO:

45 and 46.

102. The method of claim 96, further comprising measuring the expression level of at least one other biomarker selected from a COX-2, a CXCR2 and variants thereof.

103. The method of claim 102, wherein the COX-2 comprises SEQ ID NO:

2 and variants thereof, and the CXCR2 comprises SEQ ID NO;

3 and variants thereof.

104. The method of claim 102, wherein the expression level comprises measuring mRNA.

105. The method of claim 104, wherein the expression level comprises measuring cDNA.

106. The method of claim 102, wherein the measuring is via reverse transcriptase PCR.

107. The method of claim 106, wherein the measuring of IL-8 comprises PCR amplification with an oligonucleotide primer pair comprising SEQ ID NO:

45 and 46;

wherein the measuring of COX-2 comprises PCR amplification with an oligonucleotide primer pair comprising SEQ ID NO;

47 and 48; and

wherein the measuring of CXCR2 comprises PCR amplification with an oligonucleotide primer pair comprising SEQ ID NO;

49 and 50.